Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.43 |
| ▸ | XDH | P47989 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PNP | P00491 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HINT1 | P49773 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30898731 | 0.81 | TYMP (0.51) | TYMPXDHHPGDTAAR1HINT1 | |
| SCHEMBL30631042 | 0.79 | TK2 (0.42) | — | |
| SCHEMBL10394453 | 0.79 | TYMP (0.44) | TYMPXDHHPGDPNPMEN1 | |
| SCHEMBL10394454 | 0.79 | TYMP (0.44) | TYMPXDHHPGDPNPMEN1 | |
| SCHEMBL30140997 | 0.77 | TYMP (0.51) | TYMPXDHHPGDTAAR1HINT1 | |
| SCHEMBL23827266 | 0.74 | TYMP (0.48) | TYMPXDHHPGDPNPTAAR1 | |
| SCHEMBL23827221 | 0.74 | TYMP (0.48) | TYMPXDHHPGDTAAR1HINT1 | |
| SCHEMBL23827319 | 0.73 | TYMP (0.47) | TYMPXDHHPGDPNPTAAR1 | |
| SCHEMBL7897645 | 0.73 | TYMP (0.50) | TYMPXDHHPGDPNPMEN1 | |
| SCHEMBL10394457 | 0.73 | PNP (0.40) | TYMPXDHPNPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-11-06 | — | — | US | disclosed |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-06-24 | — | — | US | disclosed |
| EP-4275689-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340584-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | POLN, DDX21, MUS81 | TYMP 1322/4885XDH 2906/4885HPGD 4445/4885 |
| US-12338265-B2 | Crosslinked artificial nucleic acid ALNA | POLN, DDX21, MUS81 | TYMP 1322/4885XDH 2906/4885HPGD 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.